Longeveron (LGVN) Change in Receivables (2020 - 2026)
Longeveron's (LGVN) quarterly Change in Receivables came in at -$36000.0 in Q1 2026, up 34.55% year-on-year from -$26756.8 in Q1 2025, and down 169.23% quarter-over-quarter from $52000.0 in Q4 2025.
Longeveron (LGVN) Change in Receivables (2020 - 2026) Analysis & Trends
Longeveron's Change in Receivables history runs 7 years deep, the most recent figure standing at -$36000.0 for Q1 2026.
- On a quarterly basis, Change in Receivables rose 34.55% year-over-year to -$36000.0 in Q1 2026; TTM through Mar 2026 was $39000.0, a 126.17% increase from a year earlier, with the FY2025 full-year figure at $20000.0, up 174.07% from the prior year.
- Change in Receivables declined to -$36000.0 in Q1 2026 per LGVN's latest filing, from $52000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $162000.0 in Q3 2024 and bottomed at -$296000.0 in Q4 2024.
- The 5-year median for Change in Receivables is $40000.0 (2022), against an average of $933.33.
- Biggest YoY gain for Change in Receivables was 154.92% in 2024; the steepest drop was 2073.33% in 2024.
- Year by year, Change in Receivables stood at $42000.0 in 2022, then plunged by 64.29% to $15000.0 in 2023, then sank by 2073.33% to -$296000.0 in 2024, then soared by 117.57% to $52000.0 in 2025, then slumped by 169.23% to -$36000.0 in 2026.
- Per Business Quant, the three latest LGVN Change in Receivables figures stand at -$36000.0 (Q1 2026), $52000.0 (Q4 2025), and $21000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | -36,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36,000.00 |
| Mar 31, 2026 | -36,000.00 |
| Dec 31, 2025 | 52,000.00 |
| Dec 31, 2025 | 52,000.00 |
| Sep 30, 2025 | 21,000.00 |
| Sep 30, 2025 | 21,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | -55,000.00 |
| Mar 31, 2025 | -55,000.00 |
| Dec 31, 2024 | -296,000.00 |
| Dec 31, 2024 | -296,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Jun 30, 2024 | 40,000.00 |
| Jun 30, 2024 | 40,000.00 |
| Mar 31, 2024 | 67,000.00 |
| Mar 31, 2024 | 67,000.00 |
| Dec 31, 2023 | 15,000.00 |
| Dec 31, 2023 | 15,000.00 |